Erratum: Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: A randomized, placebo-controlled trial.
作者信息
Ebdrup Bjørn H, Broberg Brian V, Ishøy Pelle L, Bak Nikolaj, Andersen Ulrik B, Jørgensen Niklas R, Holst Jens J, Knop Filip K, Glenthøj Birte Y
机构信息
Centre for Neuropsychiatric Schizophrenia Research, CNSR, and Center for Clinical Intervention and Neuropsychiatric Schizophrenia Research, CINS, Mental Health Centre Glostrup, University of Copenhagen, Glostrup, Denmark.
Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark.
出版信息
Diabetes Obes Metab. 2018 May;20(5):1327-1328. doi: 10.1111/dom.13204. Epub 2018 Jan 23.
Abstract
摘要
相似文献
1
Erratum: Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: A randomized, placebo-controlled trial.勘误：胰高血糖素样肽-1受体激动剂治疗对肥胖的精神分裂症抗精神病药物治疗患者体重的影响：一项随机、安慰剂对照试验。
Diabetes Obes Metab. 2018 May;20(5):1327-1328. doi: 10.1111/dom.13204. Epub 2018 Jan 23.
2
No cognitive-enhancing effect of GLP-1 receptor agonism in antipsychotic-treated, obese patients with schizophrenia.GLP-1 受体激动剂对接受抗精神病药物治疗的肥胖精神分裂症患者无认知增强作用。
Acta Psychiatr Scand. 2017 Jul;136(1):52-62. doi: 10.1111/acps.12711. Epub 2017 Mar 5.
3
The effect of zonisamide on antipsychotic-associated weight gain in patients with schizophrenia: a randomized, double-blind, placebo-controlled clinical trial.左乙拉西坦对精神分裂症患者抗精神病药相关体重增加的影响：一项随机、双盲、安慰剂对照临床试验。
Schizophr Res. 2013 Jun;147(1):110-115. doi: 10.1016/j.schres.2013.03.021. Epub 2013 Apr 11.
4
Glucagon-like peptide-1 receptor agonists for antipsychotic-associated cardio-metabolic risk factors: A systematic review and individual participant data meta-analysis.胰高血糖素样肽-1 受体激动剂治疗抗精神病药物相关心代谢危险因素的系统评价和个体参与者数据荟萃分析。
Diabetes Obes Metab. 2019 Feb;21(2):293-302. doi: 10.1111/dom.13522. Epub 2018 Oct 7.
5
A novel dual glucagon-like peptide and glucagon receptor agonist SAR425899: Results of randomized, placebo-controlled first-in-human and first-in-patient trials.新型双重胰高血糖素样肽和胰高血糖素受体激动剂 SAR425899：随机、安慰剂对照的首次人体和首次住院患者试验结果。
Diabetes Obes Metab. 2019 Jan;21(1):120-128. doi: 10.1111/dom.13494. Epub 2018 Sep 16.
6
Metformin for treatment of antipsychotic-induced amenorrhea and weight gain in women with first-episode schizophrenia: a double-blind, randomized, placebo-controlled study.二甲双胍治疗首发精神分裂症女性抗精神病药所致闭经和体重增加的双盲、随机、安慰剂对照研究。
Am J Psychiatry. 2012 Aug;169(8):813-21. doi: 10.1176/appi.ajp.2012.11091432.
7
Efficacy for Psychopathology and Body Weight and Safety of Topiramate-Antipsychotic Cotreatment in Patients With Schizophrenia Spectrum Disorders: Results From a Meta-Analysis of Randomized Controlled Trials.托吡酯与抗精神病药物联合治疗精神分裂症谱系障碍患者的精神病理学、体重疗效及安全性：随机对照试验的荟萃分析结果
J Clin Psychiatry. 2016 Jun;77(6):e746-56. doi: 10.4088/JCP.15r10373.
8
Cariprazine for the Treatment of Schizophrenia: A Review of this Dopamine D3-Preferring D3/D2 Receptor Partial Agonist.卡立普嗪用于治疗精神分裂症：对这种优先作用于多巴胺D3的D3/D2受体部分激动剂的综述
Clin Schizophr Relat Psychoses. 2016 Summer;10(2):109-19. doi: 10.3371/1935-1232-10.2.109.
9
Adjunctive α-lipoic acid reduces weight gain compared with placebo at 12 weeks in schizophrenic patients treated with atypical antipsychotics: a double-blind randomized placebo-controlled study.在接受非典型抗精神病药物治疗的精神分裂症患者中，与安慰剂相比，辅助使用α-硫辛酸在12周时可减少体重增加：一项双盲随机安慰剂对照研究。
Int Clin Psychopharmacol. 2016 Sep;31(5):265-74. doi: 10.1097/YIC.0000000000000132.
10
Oral Aripiprazole as Maintenance Treatment in Adolescent Schizophrenia: Results From a 52-Week, Randomized, Placebo-Controlled Withdrawal Study.阿立哌唑口崩片作为青少年精神分裂症的维持治疗：一项为期 52 周、随机、安慰剂对照停药研究的结果。
J Am Acad Child Adolesc Psychiatry. 2017 Sep;56(9):784-792. doi: 10.1016/j.jaac.2017.06.013. Epub 2017 Jul 8.
引用本文的文献
1
The Potential Role of GLP-1 Agonists in Psychiatric Disorders: A Paradigm Shift in Mental Health Treatment.胰高血糖素样肽-1激动剂在精神疾病中的潜在作用：心理健康治疗的范式转变
Indian J Psychol Med. 2024 May;46(3):193-195. doi: 10.1177/02537176241246744. Epub 2024 Apr 12.
2
Pharmacological interventions for prevention of weight gain in people with schizophrenia.预防精神分裂症患者体重增加的药物干预。
Cochrane Database Syst Rev. 2022 Oct 3;10(10):CD013337. doi: 10.1002/14651858.CD013337.pub2.
3
Bone Status in Obese, Non-diabetic, Antipsychotic-Treated Patients, and Effects of the Glucagon-Like Peptide-1 Receptor Agonist Exenatide on Bone Turnover Markers and Bone Mineral Density.肥胖、非糖尿病、接受抗精神病药物治疗患者的骨状态，以及胰高血糖素样肽-1受体激动剂艾塞那肽对骨转换标志物和骨密度的影响。
Front Psychiatry. 2019 Jan 28;9:781. doi: 10.3389/fpsyt.2018.00781. eCollection 2018.
本文引用的文献
1
Treatment of clozapine-associated obesity and diabetes with exenatide in adults with schizophrenia: A randomized controlled trial (CODEX).阿立哌唑治疗精神分裂症患者氯氮平所致肥胖和糖尿病的随机对照试验（CODEX）
Diabetes Obes Metab. 2018 Apr;20(4):1050-1055. doi: 10.1111/dom.13167. Epub 2017 Dec 19.
2
Effect of Liraglutide Treatment on Prediabetes and Overweight or Obesity in Clozapine- or Olanzapine-Treated Patients With Schizophrenia Spectrum Disorder: A Randomized Clinical Trial.利拉鲁肽治疗对接受氯氮平或奥氮平治疗的精神分裂症谱系障碍患者前驱糖尿病及超重或肥胖的影响：一项随机临床试验
JAMA Psychiatry. 2017 Jul 1;74(7):719-728. doi: 10.1001/jamapsychiatry.2017.1220.
3
Effect of GLP-1 receptor agonist treatment on body weight in obese antipsychotic-treated patients with schizophrenia: a randomized, placebo-controlled trial.胰高血糖素样肽-1受体激动剂治疗对肥胖的精神分裂症抗精神病药物治疗患者体重的影响：一项随机、安慰剂对照试验。
Diabetes Obes Metab. 2017 Feb;19(2):162-171. doi: 10.1111/dom.12795. Epub 2016 Nov 14.
4
Treatment of antipsychotic-associated obesity with a GLP-1 receptor agonist--protocol for an investigator-initiated prospective, randomised, placebo-controlled, double-blinded intervention study: the TAO study protocol.使用胰高血糖素样肽-1受体激动剂治疗抗精神病药物相关肥胖——一项研究者发起的前瞻性、随机、安慰剂对照、双盲干预研究方案：TAO研究方案
BMJ Open. 2014 Jan 8;4(1):e004158. doi: 10.1136/bmjopen-2013-004158.
Zotero 插件